People with HIV/AIDS are at an increased risk of developing various musculoskeletal conditions, including osteoporosis, rheumatoid arthritis, and gout.

Musculoskeletal pain in people with HIV/AIDS can be caused by a combination of viral replication in the joints, immune system dysfunction, and the use of antiretroviral therapy.

Tenofovir disoproxil fumarate (TDF) is associated with an increased risk of osteonecrosis, a condition characterized by the death of bone tissue.

Treatment for HIV-associated rheumatoid arthritis typically involves a combination of nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and glucocorticoids.

HIV-associated gout can manifest as tophaceous gout, acute gouty arthritis, or chronic gouty arthritis.

The primary goal of treatment for musculoskeletal conditions in people with HIV/AIDS is to alleviate pain and inflammation, prevent disease progression, and improve joint function.

Regular exercise, maintaining a healthy weight, and avoiding tobacco and alcohol use can all help reduce the risk of musculoskeletal problems in people with HIV/AIDS.

Physical therapy can help improve range of motion, strengthen muscles, and reduce pain and inflammation in people with HIV/AIDS who have musculoskeletal conditions.

HIV-associated osteoporosis can lead to fractures, kyphosis (a humpback deformity), and loss of height.

Surgical intervention is the primary treatment for HIV-associated osteonecrosis.

HIV-associated myopathy can manifest as muscle weakness, muscle pain, and muscle atrophy.

The primary goal of treatment for HIV-associated myopathy is to improve muscle strength, reduce muscle pain and inflammation, and prevent disease progression.

HIV-associated polymyositis can lead to respiratory failure, cardiac failure, and dysphagia (difficulty swallowing).

Treatment for HIV-associated polymyositis typically involves a combination of corticosteroids, immunosuppressive drugs, and physical therapy.

HIV-associated fibromyalgia can manifest as widespread pain, fatigue, and sleep disturbances.

The primary goal of treatment for HIV-associated fibromyalgia is to relieve pain and fatigue, improve sleep quality, and enhance physical function.